Home > Healthcare & Medical Devices > Stem Cell Therapy Market

Stem Cell Therapy Market Size By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics), COVID-19 Impact Analysis, Regional Outlook, Technology Potential, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI3331
  • Published Date: Dec 2021
  • Report Format: PDF

Industry Trends

Stem Cell Therapy Market size surpassed USD 8.9 billion in 2020 and is expected to witness growth rate of over 10.6% from 2021 to 2027. Constant government support and initiatives for research and development activities of regenerative medicine in developed areas is likely to drive the industry demand. For instance, according to the government of Australia, the Medical Research Future Fund’s (MRFF) announced Stem Cell Therapies Mission as a part of the 2019-20 budget. The government funded nearly USD 150 million for research and development of safe and effective treatments accessible to all diseased population.

Get more details on this report - Request Free Sample PDF

The global spread of COVID-19 infection did not have material effect on the industry. Various research institutes and government organizations across the regions were focusing on rapid and effective technologies for the treatment of life-threatening diseases including COVID-19 outbreak. Moreover, several clinical trials were begun with respective to regenerative medicine. However, it is in the initial stage of study in relation to the various different single umbilical cord stem cell market studied.


Rising prevalence of rare genetic diseases

Increasing prevalence of rare genetic diseases is anticipated to augment the stem cell therapy market growth. Every year, millions of people suffer from rare diseases such as thalasemmia, phenylketonuria, cystic fibrosis and others. For instance, according to the Firstpost report, in 2020, there were 40 million carriers of thalasemmia in India, which represent one in eight of thalassemia carriers in India. Therefore, conventional therapies and medications have proven less effective in curing these diseases and thus, individuals have now started preferring advanced stem cell therapies that should elevate the industry statistics. Furthermore, advances in stem cell therapies that improve recovery speed in patients suffering from malignancies is expected to boost demand.

Ethical issues associated with stem cell therapy may slow the market

Several safety and ethical issues are associated with the use of stem cells, as these stem cells are derived from the human embryo, thereby limiting the development of human embryonic stem cell (hESC). Additionally, deriving pluripotent stem cell lines from embryos and oocytes is an intense topic of disputes. Medical risks associated with the oocyte retrieval and several other risks related to experimental interventions may impact the demand for stem cell therapies negatively.

Autologous stem cell process is tedious and time consuming

Autologous stem cell therapy segment is projected to grow at around 10.5% through 2027. The autologous stem cell therapy provides high compatibility with human’s immune system, as the patients are their own donors of stem cell. Similarly, the risk of graft rejection is less and the possibilities of using these cells without undergoing clinical trial is poised to spur the market revenue. However, these stem cells require tremendous degree of manipulation and may even need gene modification. Hence, the overall process is tedious and time consuming that may lower the pace of segmental growth.

High success rate of stem cell therapies in treatment of various form of cancer

Get more details on this report - Request Free Sample PDF

Oncology segment accounted for about 37.1% of the stem cell therapy market share in 2020 and is predicted to observe similar trends through 2027. Increasing prevalence of cancer cases coupled with high success rate of stem cell therapies in treatment of cancer is propelling the market expansion. For instance, as per the Memorial Sloan Kettering Cancer Center, the predicted rate of one-year survival for patients undergoing an allogeneic bone marrow transplantation was more than 60%.

Hospitals are collaborating with research institute to upgrade its treatment offering

Hospitals end-use segment is estimated to register nearly 10.6% gains till 2027. Growing preference for stem cell therapies provided in hospitals to avoid complications caused owing to the invasive methods including surgical procedures is spurring the industry size. Currently, hospitals are affiliated with research laboratories and academic institutes that conducts extensive research for the development of innovative stem cell therapies. Collaborations with research institutes allow hospitals to upgrade its treatment offerings, thereby, positively influence the market statistics.

High favorable government activities in North America

Get more details on this report - Request Free Sample PDF

North America stem cell therapy market valued at USD 3.7 billion in 2020 and is forecast to expand at 10.3% CAGR from 2021 to 2027. Considerable regional growth can be attributed to the favourable government initiatives. For instance, in November 2020, government of Canada and JDRF Canada announced a new research funding of USD 6 million to accelerate stem cell-based therapies for type 1 diabetes. In addition, technological advancements in regenerative medicine will further support the market demand.

Growth strategies of market players are focused on increasing the customer base

Few of the notable stem cell therapy market players are Astellas Pharma Inc, Novadip Biosciences, MEDIPOST, Fujifilm Cellular Dynamics, DiscGenics, Mesoblast Ltd and Takeda Pharmaceutical among others. Companies adopt strategies such as novel product launch, mergers and acquisitions to foster business.

Recent industry developments:

  • In March 2021, Novadip Biosciences received approval from U.S. FDA for the Company’s Investigational New Drug (IND) application for its autologous cell therapy product NVD-003. The product is used for the treatment of Congenital Pseudarthrosis of the Tibia (CPT). This strategy is likely to enhance their product offerings and expand their customer base, thereby strengthening its market position.
  • In January 2020, Astellas Pharma Inc. entered into the licensing agreement with Allele Biotechnology and Pharmaceuticals, Inc., a company engaged in the development of cell-based therapeutics. This agreement aimed at expanding Astellas access to Allele’s induced pluripotent stem cell (iPSC) technologies for various cell therapy. This strategy enabled company to offer innovative solution as well as maintain its long-term business relation.

This stem cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments

Market, By Type

  • Allogenic stem cell therapy
  • Autologous stem cell therapy

Market, By Therapeutic Area

  • Oncology
  • Orthopedic
  • Cardiovascular
  • Neurology
  • Others

Market, By End-use

  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The market for stem cell therapy exceeded USD 8.9 billion in 2020 and is set to grow at a CAGR of 10.6% between 2021 and 2027, says this GMI report.
Autologous stem cell therapy will record a growth rate of around 10.5% through 2027 given that the therapy is highly compatible with the human immune system.
The oncology segment accounted for 37.1% of the industry share in 2020 and will expand with rising prevalence of cancer cases and high success rate of stem cell therapies in cancer treatment.
North America market is anticipated to witness 10.3% growth up to 2027 driven by the favorable government initiatives in the region.
Leading companies across the industry include MEDIPOST, Astellas Pharma Inc., DiscGenics, Novadip Biosciences, Mesoblast Ltd., Fujifilm Cellular Dynamics, Takeda Pharmaceutical, and others.

Buy Now

Premium Report Details

  • Base Year: 2020
  • Companies covered: 10
  • Tables & Figures: 104
  • Countries covered: 18
  • Pages: 110
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount